Sofinnova Venture Partners X, L.P. ("SVP X") 13D and 13G filings for Aerovate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-20 7:09 pm Purchase | 2023-06-21 | 13D | Aerovate Therapeutics, Inc. AVTE | Sofinnova Venture Partners X, L.P. ("SVP X") | 108,780 13.800% | 677 (+0.63%) | Filing |
| 2023-02-03 7:24 pm Purchase | 2022-11-14 | 13D | Aerovate Therapeutics, Inc. AVTE | Sofinnova Venture Partners X, L.P. ("SVP X") | 108,104 15.400% | 673 (+0.63%) | Filing |
| 2021-07-13 1:49 pm Purchase | 2021-07-02 | 13D | Aerovate Therapeutics, Inc. AVTE | Sofinnova Venture Partners X, L.P. ("SVP X") | 107,431 16.300% | 107,431 (New Position) | Filing |